# Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

> **NCT03618654** · EARLY_PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 38 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Metformin
- **BIOLOGICAL:** Durvalumab

## Key facts

- **NCT ID:** NCT03618654
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2021-11-20
- **Final completion:** 2022-12-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03618654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03618654, "Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03618654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*